The Blockchain Futurist Conference, held August 13-14 in Toronto, is Canada’s largest crypto, Web3 and blockchain conference. This year’s highlights included: Key to the event are panel discussions, which spotlight areas of interest and allow attendees to hear and meet with topic experts. These moderated discussions offer ideas and answers from business and technology leaders […]

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released findings from its applied research program that sought to evaluate the mode of action facets of its patented DehydraTECH(TM) technology and the glucagon-like peptide 1 (“GLP-1”) drug, semaglutide. The program was conducted in conjunction with the National Research Council of Canada (“NRC”), […]

Electronic monitoring (“EM”) technology innovator SuperCom (NASDAQ: SPCB) is celebrating impressive developments in 2024, reporting “substantial improvements” in its gross profit, operating income, and net income as it secures new orders and contracts from government and judicial system clients. SuperCom’s technology development and deployment are strategically focused on providing EM tools for tracking offenders supervised […]

In 1901, the then-45-year-old Burberry, now a renowned British luxury fashion house, ran a public competition seeking a winning entry that would become the new logo for the company. The winning entry was the equestrian knight design (“EKD”), a testimony to the company’s relationship with its communities. The EKD depicted an armor-clad knight riding a […]

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter ended June 30, 2024. The company reported productive recent months, with encouraging data on lead compound buntanetap’s performance […]

InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes from a long-term preclinical study of its Alzheimer’s Disease (“AD”) drug candidate, INM-901. These new findings confirm and expand upon results from a previous short-term pilot study (https://ibn.fm/eASUI). The long-term […]

SenesTech (NASDAQ: SNES), the inventor of ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, as well as Evolve(R) and Evolve Mouse(R), EPA-designated minimum risk contraceptives for rodents, recently reported financial results for its second quarter of fiscal 2024, ended June 30, 2024. In addition, Joel Fruendt, President and CEO of SenesTech, and […]

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced positive results of two independently conducted Phase 2 clinical trials, RESCUE-ALS and HEALEY ALS Platform Trials, of CNM-Au8 for the treatment of amyotrophic lateral sclerosis (“ALS”) (https://ibn.fm/ktu4u). The new CNM-Au8 biomarker and clinical […]

The National Investment Banking Association (“NIBA”) invites the micro-cap and small-cap investment community to its 150th investment conference. The event will be held on September 4-5, 2024, at the Westin Fort Lauderdale Beach Resort, Ft. Lauderdale, Florida. Since 1982, The National Investment Banking Association has been a not-for-profit association for the micro-cap and small-cap investment […]

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the first commercial provider of quantum computers, released its second quarter 2024 financial results along with recent business and technical updates. The company reported growth in key areas, reflecting its continued momentum in the quantum computing market (https://ibn.fm/DNZ11). D-Wave has made […]